Latest Northwest Biotherapeutics (NWBO) Headlines
3 Stocks Making Health-Care Investors Big Money Today
David Williamson, The Motley Fool - Motley Fool - 1 hr 44 mins ago
Despite an overall down day on the market today, the health-care sector emerged looking pretty good, with a handful of big winners. In this video, Motley Fool health-care analyst David Williamson looks at three top performers. Regado Biosciences ...
Nasdaq stocks posting largest percentage increases
AP - 2 hrs 31 mins ago
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Why Northwest Biotherapeutics, Ballard Power Systems, and Plug Power Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Mon Mar 10, 4:15PM CDT
With no domestic economic news on the docket, the broad-based S&P 500 took its early cues from the Shanghai Composite which fell nearly 3% overnight following abysmal Chinese export data . Overseas shipments from China dipped 18.1% in...
Why Northwest Biotherapeutics, Inc. Shares Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - Mon Mar 10, 1:24PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Northwest Biotherapeutics , a...
NW Bio Announces Two German Approvals: "Hospital Exemption" for Early Access Program with DCVax-L and Eligibility of DCVax-L for Reimbursement
PR Newswire Europe - Mon Mar 10, 7:03AM CDT
- DCVax-L Is First Product of Its Kind to Receive Hospital Exemption from German Regulator
Risk of Pivotal Study Failure Rises for NewLink and Northwest Bio
at The Street - Fri Mar 07, 9:51AM CST
A closer look at the interim analyses for two cancer vaccine trials reveals potential problems.
NW Bio Receives Recommendation To Continue With Phase III GBM Brain Cancer Trial Based On Data Safety Monitoring Board's Safety Review
PR Newswire - Fri Mar 07, 7:00AM CST
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today, in response to shareholder inquiries, that the Data Safety Monitoring Board (DSMB) has made an unblinded review of the safety data for the Company's ongoing international Phase III GBM Trial, and has recommended that the trial continue as planned.
Northwest Bio: Interim Analysis of Brain Cancer Vaccine Study Past Due
at The Street - Mon Mar 03, 9:32AM CST
Twelve weeks have passed since Northwest Bio said an interim analysis of the DCVax phase III study was underway. Where are the results?
5 Stocks Poised for Breakouts
at The Street - Fri Feb 21, 12:53PM CST
These stocks look ready to break out and trade higher from current levels.
China Insulin Delivery Devices Market Outlook and Trends Till 2018
PR Newswire - Tue Feb 11, 7:15AM CST
Reportbuyer.com just published a new market research report:
NW Bio to Present at BIO CEO and Investor Conference 2014
PR Newswire - Thu Feb 06, 7:15AM CST
Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that Linda F. Powers, CEO, will present at the BIO CEO and Investor Conference 2014, which is being held in New York on February 10-11, 2014.
RPC, Inc. Announces a 5 Percent Increase to the Regular Quarterly Cash Dividend
PR Newswire - Wed Jan 29, 6:15AM CST
RPC, Inc. (NYSE: RES) announced today that its Board of Directors declared a 5.0 percent increase to the regular quarterly cash dividend from $0.10 per share to $0.105, or 10.5 cents, per share payable March 10, 2014 to common stockholders of record at the close of business on February 10, 2014.
Why Northwest Biotherapeutics, Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Mon Jan 27, 3:03PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Northwest Biotherapeutics , a...
NW Bio Enters Into Agreements For Large-Scale Expansion Of Product Manufacturing, Handling And Distribution
PR Newswire - Mon Jan 27, 7:16AM CST
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has entered into a set of agreements for large-scale expansion of the manufacturing, storage, handling and distribution of its DCVax-L and DCVax-Direct products, development of infrastructure and key systems, and execution of product validation work required for any eventual regulatory approvals, with the Company's long-time contract manufacturer, Cognate Bioservices, Inc. ("Cognate").
3 Stocks Making Health-Care Investors Big Money Today
David Williamson, The Motley Fool - Motley Fool - 1 hr 44 mins ago
Despite an overall down day on the market today, the health-care sector emerged looking pretty good, with a handful of big winners. In this video, Motley Fool health-care analyst David Williamson looks at three top performers. Regado Biosciences ...
Nasdaq stocks posting largest percentage increases
AP - 2 hrs 31 mins ago
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Why Northwest Biotherapeutics, Ballard Power Systems, and Plug Power Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Mon Mar 10, 4:15PM CDT
With no domestic economic news on the docket, the broad-based S&P 500 took its early cues from the Shanghai Composite which fell nearly 3% overnight following abysmal Chinese export data . Overseas shipments from China dipped 18.1% in...
Why Northwest Biotherapeutics, Inc. Shares Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - Mon Mar 10, 1:24PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Northwest Biotherapeutics , a...
NW Bio Announces Two German Approvals: "Hospital Exemption" for Early Access Program with DCVax-L and Eligibility of DCVax-L for Reimbursement
PR Newswire Europe - Mon Mar 10, 7:03AM CDT
- DCVax-L Is First Product of Its Kind to Receive Hospital Exemption from German Regulator
Risk of Pivotal Study Failure Rises for NewLink and Northwest Bio
at The Street - Fri Mar 07, 9:51AM CST
A closer look at the interim analyses for two cancer vaccine trials reveals potential problems.
NW Bio Receives Recommendation To Continue With Phase III GBM Brain Cancer Trial Based On Data Safety Monitoring Board's Safety Review
PR Newswire - Fri Mar 07, 7:00AM CST
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today, in response to shareholder inquiries, that the Data Safety Monitoring Board (DSMB) has made an unblinded review of the safety data for the Company's ongoing international Phase III GBM Trial, and has recommended that the trial continue as planned.
Northwest Bio: Interim Analysis of Brain Cancer Vaccine Study Past Due
at The Street - Mon Mar 03, 9:32AM CST
Twelve weeks have passed since Northwest Bio said an interim analysis of the DCVax phase III study was underway. Where are the results?
5 Stocks Poised for Breakouts
at The Street - Fri Feb 21, 12:53PM CST
These stocks look ready to break out and trade higher from current levels.
China Insulin Delivery Devices Market Outlook and Trends Till 2018
PR Newswire - Tue Feb 11, 7:15AM CST
Reportbuyer.com just published a new market research report:
NW Bio to Present at BIO CEO and Investor Conference 2014
PR Newswire - Thu Feb 06, 7:15AM CST
Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that Linda F. Powers, CEO, will present at the BIO CEO and Investor Conference 2014, which is being held in New York on February 10-11, 2014.
RPC, Inc. Announces a 5 Percent Increase to the Regular Quarterly Cash Dividend
PR Newswire - Wed Jan 29, 6:15AM CST
RPC, Inc. (NYSE: RES) announced today that its Board of Directors declared a 5.0 percent increase to the regular quarterly cash dividend from $0.10 per share to $0.105, or 10.5 cents, per share payable March 10, 2014 to common stockholders of record at the close of business on February 10, 2014.
Why Northwest Biotherapeutics, Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Mon Jan 27, 3:03PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Northwest Biotherapeutics , a...
NW Bio Enters Into Agreements For Large-Scale Expansion Of Product Manufacturing, Handling And Distribution
PR Newswire - Mon Jan 27, 7:16AM CST
Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has entered into a set of agreements for large-scale expansion of the manufacturing, storage, handling and distribution of its DCVax-L and DCVax-Direct products, development of infrastructure and key systems, and execution of product validation work required for any eventual regulatory approvals, with the Company's long-time contract manufacturer, Cognate Bioservices, Inc. ("Cognate").
